Arovella Therapeutics Limited

Arovella Therapeutics Limited is an Australia-based biotechnology company. The Company is focused on developing therapies to treat human disease. The Company focuses two focus areas are oncology and conditions that impact the central nervous system. The Company's technology includes iNKT Cell Therapy, DKK1-CAR-iNKT, AR19-iNKT + CF33-CD19, Anagrelide and ZolpiMist. The Company's invariant natural killer T (iNKT) cell therapy pipeline through the license to the DKK1 monoclonal antibody (mAb). It develops the DKK1 mAb as a chimeric antigen receptor to use in combination with its iNKT cell therapy platform. The Company is developing its invariant natural killer T (iNKT) cell therapy platform from Imperial College London to treat blood cancers and solid tumors. Anagrelide is for the treatment of metastatic disease granted in the United States, Europe, Japan and Australia. ZolpiMist is an oral spray of zolpidem tartrate to treat short- term insomnia.